Please login to the form below

Not currently logged in

Study highlights poor diabetes consultation

Less than a third of patients asked for input into their treatment plans

Results from a global study have shown that only 29 per cent of people with diabetes across the world report that their healthcare team ask for their input when making their treatment plans.

Only 33 per cent of the 15,000 respondents to the Diabetes Attitudes, Wishes and Needs 2 study (DAWN2) said they were encouraged by their healthcare professional to ask questions in the consultation.

The study was led by the diabetes-focused pharma company Novo Nordisk in collaboration with the International Diabetes Federation (IDF), the International Alliance of Patients' Organizations (IAPO), the Steno Diabetes Center and other partners.

The organisations said they were surprised at these results, “given the importance of active involvement of people with diabetes in their own treatment and care”.

A significant number of the healthcare professionals who took part in the study felt that people with diabetes needed to do more - 84 per cent said it would be helpful if their patients prepared questions in advance of consultations.

IDF president Sir Michael Hirst commented: “The study calls for united efforts across stakeholders and nations to advance a person-centred approach to improve prevention, care, education and support for people with diabetes and their families.”

Ingrid Willaing, head of education research at the Steno Diabetes Center: “People with diabetes who feel supported and capable of self-managing their condition are more likely to have a successful treatment outcome.”

The study will be used internationally and nationally to facilitate dialogue among patient organisations, healthcare professionals and other key stakeholders to develop action plans for improvement of the lives of people with diabetes.

Article by
Tara Craig

10th December 2013

From: Marketing, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...